PSYCHEMEDICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.54 USD | -0.39% |
|
-1.17% | -14.19% |
| Mar. 28 | Psychemedics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 25.24M | Sales 2023 | 22.1M | Capitalization | 17.17M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -4M | EV / Sales 2022 | 1.05 x |
| Net cash position 2022 | 1.18M | Net Debt 2023 | 334K | EV / Sales 2023 | 0.79 x |
| P/E ratio 2022 |
-25.5
x | P/E ratio 2023 |
-4.09
x | Employees | 116 |
| Yield 2022 |
5.71% | Yield 2023 |
2.36% | Free-Float | 69.33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.39% | ||
| 1 week | -1.17% | ||
| Current month | -1.74% | ||
| 1 month | -11.81% | ||
| 3 months | -16.17% | ||
| 6 months | +12.39% | ||
| Current year | -14.19% |
1 week
2.53
2.70
1 month
2.512.90
Current year
2.513.93
1 year
2.065.49
3 years
2.068.90
5 years
2.0610.95
10 years
2.0627.99
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Hullinger
CEO | Chief Executive Officer | 56 | 23-08-16 |
Daniella Mehalik
DFI | Director of Finance/CFO | 34 | Nov. 26 |
| Corporate Officer/Principal | 38 | 23-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Kamin
BRD | Director/Board Member | 62 | 22-08-11 |
Darius Nevin
CHM | Chairman | 66 | 22-08-11 |
Robyn Davis
BRD | Director/Board Member | 63 | 21-03-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 2.54 | -0.39% | 2,050 |
| 24-05-03 | 2.55 | -3.27% | 721 |
| 24-05-02 | 2.636 | +0.62% | 3,481 |
| 24-05-01 | 2.62 | +1.35% | 1,960 |
| 24-04-30 | 2.585 | +0.58% | 18,478 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotes
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.19% | 14.75M | |
| -17.02% | 8.36B | |
| +49.55% | 3.84B | |
| -8.58% | 2.48B | |
| -34.62% | 2.64B | |
| -9.88% | 2.33B | |
| -4.14% | 1.98B | |
| -17.46% | 1.6B | |
| -37.88% | 1.27B | |
| +8.08% | 1.11B |
- Stock Market
- Equities
- PMD Stock